(Q33867830)

29 July 2017

1 reference

title

Abciximab. A pharmacoeconomic review of its use in percutaneous coronary revascularisation (English)

1 reference

29 July 2017

1 reference

C J Dunn

1

1 reference

29 July 2017

R H Foster

series ordinal

2

1 reference

29 July 2017

publication date

1 December 1999

1 reference

29 July 2017

1 reference

29 July 2017

volume

16

1 reference

29 July 2017

issue

6

1 reference

29 July 2017

page(s)

711-741

1 reference

https://scigraph.springernature.com/pub.10.2165/00019053-199916060-00009

29 July 2017

exact match

0 references

cites work

Safe use of platelet GP IIb/IIIa inhibitors.

1 reference

12 December 2020

Management of acute myocardial infarction. Synopsis of ACC and AHA practice guidelines. American College of Cardiology and American Heart Association

1 reference

12 December 2020

Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction

1 reference

12 December 2020

Trends in success rate after percutaneous transluminal coronary angioplasty in men and women with coronary artery disease

1 reference

12 December 2020

Analysis of coronary angioplasty practice in the United States with an insurance-claims data base

1 reference

12 December 2020

Coronary angioplasty outcomes in the Healthcare Cost and Utilization Project, 1993-1994.

1 reference

12 December 2020

Indications for intracoronary stent placement: the european view. Working Group on Coronary Circulation of the European Society of Cardiology

1 reference

12 December 2020

Preferential benefit of platelet glycoprotein IIb/IIIa receptor blockade: specific considerations by device and disease state

1 reference

12 December 2020

Murmurs from the heart (or why the stethoscope is not an economic tool)

1 reference

12 December 2020

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

1 reference

12 December 2020

Cost advantages of an ad hoc angioplasty strategy

1 reference

12 December 2020

Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Compl

1 reference

12 December 2020

Effectiveness and cost effectiveness of single bolus treatment with abciximab (Reo Pro) in preventing restenosis following percutaneous transluminal coronary angioplasty in high risk patients

1 reference

12 December 2020

Platelet GPIIb-IIIa blockers

1 reference

12 December 2020

The Economics of IIb/IIIa Therapy

1 reference

12 December 2020

Acute myocardial infarction: pre-hospital and in-hospital management. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology

1 reference

12 December 2020

Coronary artery stents. American College of Cardiology.

1 reference

12 December 2020

Cost-effectiveness analysis of abciximab: a Canadian hospital perspective

1 reference

12 December 2020

A cost-effective analysis of primary coronary angioplasty versus thrombolysis for acute myocardial infarction

1 reference

12 December 2020

Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

1 reference

12 December 2020

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

12 December 2020

Economics of elective coronary revascularization. Comparison of costs and charges for conventional angioplasty, directional atherectomy, stenting and bypass surgery.

1 reference

12 December 2020

A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators

1 reference

12 December 2020

Restenosis: the cost to society.

1 reference

12 December 2020

ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)

1 reference

12 December 2020

Abciximab therapy in percutaneous intervention: economic issues in the United States

1 reference

12 December 2020

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

12 December 2020

In-hospital and one-year economic outcomes after coronary stenting or balloon angioplasty. Results from a randomized clinical trial. Stent Restenosis Study Investigators

1 reference

12 December 2020

Evidence for Prevention of Death and Myocardial Infarction With Platelet Membrane Glycoprotein IIb/IIIa Receptor Blockade by Abciximab (c7E3 Fab) Among Patients With Unstable Angina Undergoing Percutaneous Coronary Revascularization fn1fn1This study

1 reference

12 December 2020

The Stentor and the sea change

1 reference

12 December 2020

Use of coronary angiography and revascularization procedures following acute myocardial infarction. A European perspective.

1 reference

12 December 2020

Panel 3: methodological issues in conducting pharmacoeconomic evaluations--retrospective and claims database studies

1 reference

12 December 2020

Economic evaluation in support of national health policy: the case of The Netherlands

1 reference

12 December 2020

Management of stable angina pectoris. Recommendations of the Task Force of the European Society of Cardiology

1 reference

12 December 2020

Clinical experience with abciximab during coronary revascularisation: an overview

1 reference

12 December 2020

Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators

1 reference

12 December 2020

Geographic, demographic, and socioeconomic variations in the investigation and management of coronary heart disease in Scotland.

1 reference

12 December 2020

Direct and indirect cost of percutaneous transluminal coronary angioplasty

1 reference

12 December 2020

Subacute stent thrombosis: evolving issues and current concepts

1 reference

12 December 2020

Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications

1 reference

12 December 2020

Costs, effects and C/E-ratios alongside a clinical trial.

1 reference

12 December 2020

Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa Receptors

1 reference

12 December 2020

Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.

1 reference

12 December 2020

Costs of stenting for acute myocardial infarction

1 reference

12 December 2020

Costs and effects of c7E3 in high risk PTCA patients. An indirect analysis for The Netherlands

1 reference

12 December 2020

Cost comparison of immediate angioplasty versus thrombolysis followed by conservative therapy for acute myocardial infarction: a randomized prospective trial. Mayo Coronary Care Unit and Catheterization Laboratory Groups

1 reference

12 December 2020

Abciximab. An updated review of its use in ischaemic heart disease

1 reference

12 December 2020

Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators

1 reference

12 December 2020

Use of abciximab (c7E3 Fab, ReoPro) as an adjunct to balloon angioplasty.

1 reference

12 December 2020

Shorter hospital stays for angioplasty patients who receive abciximab

1 reference

12 December 2020

Economic impact of angioplasty salvage techniques, with an emphasis on coronary stents: a method incorporating costs, revenues, clinical effectiveness and payer mix

1 reference

12 December 2020

A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators

1 reference

12 December 2020

Diagnosing and managing unstable angina. Unstable Angina Guideline Panel. Agency for Health Care Policy and Research

1 reference

12 December 2020

Enthusiasm, reality, and cost-effectiveness analysis

1 reference

12 December 2020

Long-term clinical follow-up in patients with angiographic restudy after successful angioplasty.

1 reference

12 December 2020

Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease

1 reference

12 December 2020

Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study

1 reference

12 December 2020

Readministration of abciximab: interim report of the ReoPro readministration registry

1 reference

12 December 2020

A risk-benefit assessment of abciximab in angioplasty

1 reference

12 December 2020

Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). The ERASER Investigators

1 reference

12 December 2020

Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators

1 reference

12 December 2020

Initial cost of primary angioplasty for acute myocardial infarction

1 reference

12 December 2020

Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy.

1 reference

12 December 2020

Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries

1 reference

12 December 2020

Cost and outcomes analysis of abciximab use in a community teaching hospital.

1 reference

12 December 2020

Baseline and 6-month costs of primary angioplasty therapy for acute myocardial infarction: results from the primary angioplasty registry.

1 reference

12 December 2020

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

1 reference

12 December 2020

Guidelines for managing patients with unstable angina. Rating the evidence and rationale for treatment

1 reference

12 December 2020

Clinical Benefit within Patient Subgroups Receiving c7E3 Fab (Abciximab) During Percutaneous Coronary Revascularization: Subgroup Analysis from the EPIC Trial

1 reference

12 December 2020

A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group

1 reference

12 December 2020

Care of the patient and management of complications after percutaneous coronary artery interventions

1 reference

12 December 2020

Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade

1 reference

12 December 2020

Recent trends in acute coronary heart disease--mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators.

1 reference

12 December 2020

10.2165/00019053-199916060-00009

Identifiers

DOI

1 reference

Dimensions Publication ID

29 July 2017

1039159215

0 references

Fatcat ID

release_e2plwkccrvfvtk5sfa7demhucq

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/e2plwkccrvfvtk5sfa7demhucq

24 November 2022

mapped directly with Wikidata item

1 reference